Collegium Pharmaceutical logo
COLLCollegium Pharmaceutical
Trade COLL now
Collegium Pharmaceutical primary media

About Collegium Pharmaceutical

Collegium Pharmaceutical (NASDAQ:COLL) is a specialized company focusing on the development and commercialization of innovative therapies for pain management. The company aims to address the significant challenges in the pain management sector, such as the need for safer, abuse-deterrent formulations. Collegium Pharmaceutical is passionate about improving the lives of people suffering from pain and chronic conditions, guiding its project selection and research strategies towards achieving this goal. With a strong commitment to patient care, the company continuously seeks to advance its product portfolio through rigorous research and development, while also exploring strategic partnerships and acquisitions to expand its market reach. The objectives of Collegium Pharmaceutical revolve around delivering high-quality, effective treatments, and ensuring accessibility to those in need, thereby making a meaningful difference in the healthcare landscape.

What is COLL known for?

Snapshot

Public US
Ownership
2002
Year founded
231
Employees
Massachusetts, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Collegium Pharmaceutical

  • Xtampza ER (oxycodone hydrochloride and naloxone hydrochloride) Extended-Release Tablets: A prescription pain medication used to manage moderate to severe chronic pain when other pain medications are not strong enough.
  • Nucynta (hydrocodone bitartrate and acetaminophen) Tablets: A prescription pain medication used to manage moderate to severe pain when other pain medications are not strong enough.
  • Development Pipeline: Collegium also has a development pipeline of potential future products focused on pain management and addiction treatment.

equipe executiva do Collegium Pharmaceutical

  • Mr. Vikram KarnaniCEO, President, Executive VP & Director
  • Ms. Colleen TupperExecutive VP & CFO
  • Mr. Scott DreyerExecutive VP & Chief Commercial Officer
  • Dr. Thomas B. Smith FAAFP, M.D.Executive VP & Chief Medical Officer
  • Mr. Ian Karp M.B.A.Head of Investor Relations
  • Mr. David DieterExecutive VP, General Counsel & Corporate Secretary
  • Ms. Jane GonnermanExecutive Vice President of Strategy & Corporate Development
  • Mr. Dean J. PatrasChief People Officer
  • Mr. Scott SudduthHead of Technical Operations

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.